FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and... | April 17, 2023

Related Keywords

Canada ,Canadian ,Lakshmi Kotra ,Pharma Inc ,Ms International Foundation Atlas ,Company Phase ,Nasdaq ,Biosciences Inc ,Company Annual Report On Form ,Market Research ,Lucid Psychss Inc ,Exchange Commission ,Ms Society ,Multiple Sclerosis ,Lucid Psycheceuticals ,New Chemical Entity ,Allied Market Research ,Psychss Inc ,Canadian Securities Administrators ,Annual Report ,Fsd Pharma Inc Stock Exchange ,News ,Information ,Press Release ,Sd ,Dharma ,Iopharmaceutical ,Company ,Edicated ,O ,Building ,Portfolio ,F ,Nnovative ,Assets ,End ,Biotech ,Solutions ,Or ,The ,Treatment ,Challenging ,Nflammatory Huge Ca35954b2066 ,